论文部分内容阅读
随机将４７例脑梗塞患者分成二组，分别采用东菱克栓酶（ＤＦ－５２１）及低分子右旋糖酐丹参（低右组）治疗，并同时观察疗效及检测治疗前后血浆组织型纤溶酶原激活剂（ｔ－ＰＡ）、Ｄ－二聚体（Ｄ－ｄｉｍｅｒ）值。结果表明，急性脑梗塞治疗前血浆中ｔ－ＰＡ明显低于对照组（Ｐ＜０．０５），Ｄ－ｄｉｍｅｒ明显高于对照组（Ｐ＜０．００１）；治疗后ｔ－ＰＡ较治疗前增加，以ＤＦ－５２１组为明显（Ｐ＜０．００５，低右组Ｐ＞０．０５）。用药后二组Ｄ－ｄｉｍｅｒ相比较有显著差异（Ｐ＜０．０１）；ｔ－ＰＡ相比也有差异（Ｐ＜０．０５）。ＤＦ－５２１组治疗脑梗塞有效率明显优于低右组（Ｐ＜０．０５）。提示：早期使用ＤＦ－５２１能增加纤溶酶活性，促进血栓溶解，加速神经功能恢复。
Forty-seven patients with cerebral infarction were randomly divided into two groups. They were treated with DF-521 and low molecular weight dextran (low right group) respectively. At the same time, the curative effect and plasma level of plasminogen Activator (t-PA), D-dimer value. The results showed that t-PA in plasma before acute cerebral infarction was significantly lower than that in control group (P <0.05), D-dimer was significantly higher than that in control group (P <0.001) Increased to DF-521 group was significantly (P <0.005, low right group P> 0.05). There was significant difference (P <0.01) between the two groups of D-dimer after treatment and t-PA (P <0.05). The effective rate of DF-521 group in treating cerebral infarction was significantly better than that of the low right group (P <0.05). Tip: early use of DF-521 can increase plasmin activity, promote thrombolysis, accelerate nerve function recovery.